Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
Journal
Journal of the Formosan Medical Association
Journal Volume
120
Journal Issue
4
Pages
1051
Date Issued
2021-04
Author(s)
Wang, Shen-Yung
Lin, Shi-Ming
Chen, Kuan-Yang
Tseng, Jeng-Hwei
Lee, Rheun-Chuan
Liao, Li-Ying
Hu, Jui-Ting
Kee, Kwong-Ming
Lin, Chih-Lin
Wang, Chung-Kwe
Lu, Sheng-Nan
Wang, Jing-Houng
Lee, Wei-Chen
Huang, Yi-Hsiang
Wang, Chia-Chi
Wang, Tsang-En
Chuang, Po-Heng
Dai, Chia-Yen
Chen, San-Chi
Hsieh, Chia-Hsun
Abstract
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality in Taiwan. The Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan had established a management consensus guideline in 2016. The current recommendations focus on updating critical issues regarding the management of HCC, including surveillance, diagnosis, and systemic treatment. For surveillance, the updated guideline suggests the role of dynamic computed tomography or magnetic resonance imaging and contrast-enhanced ultrasound (CEUS) in selected patients. For diagnosis, this update incorporates CEUS and recognizes the role of gadoxetic acid-enhanced magnetic resonance imaging. For systemic therapy, the updated guideline summarizes the multiple choices of targeted therapy, immune checkpoint inhibitors, and the combination of both. Through this update of the management consensus guideline, patients with HCC can benefit from receiving optimal diagnostic and therapeutic modalities.
Subjects
Diagnosis
Guideline
Hepatocellular carcinoma
Surveillance
Systemic treatment
Publisher
ELSEVIER TAIWAN
Type
journal article